Insights On CONTRACT PHARMA MANUFACTURING

  1. Amorphous Solid Dispersions: Pre-Clinical To Commercial Capabilities 7/29/2025

    ASDs are an attractive option for commercializing poorly soluble compounds. This talk focuses on capabilities to screen the potential for ASDs in early phase studies and their commercial applicability.

  2. Your Integrated Drug Substance Partner 7/29/2025

    With capabilities to support your next small molecule drug substance program from R&D to commercial scale, learn about our integrated facilities, project teams, and available capacity.

  3. Management Strategies For Adaptive Bio And Single-Use Excellence 7/28/2025

    Single-use technologies (SUTs) bring speed and flexibility to modern biomanufacturing, but realizing their full value requires robust, stage-specific risk management to navigate material, supply chain, and regulatory challenges.

  4. Drug Product Development Of Poorly Soluble Compounds 7/28/2025

    Eurofins CDMO Alphora offers comprehensive drug product development and manufacturing, specializing in poorly soluble compounds, clinical manufacturing, and integrated solutions for diverse clients.

  5. Aragen Capacity Update July 2025: Small Molecule Drug Substance/API 7/28/2025

    Explore specialized expertise in solving challenging small molecule formulation problems (poor solubility, bioavailability, complex delivery routes).

  6. Resilience Capacity Update July 2025: Large Molecule Drug Substance 7/28/2025

    Hear from Evan Pasenello, Head of Commercial Services, about how Resilience can support large molecule programs from early phase through clinical and commercial manufacturing.

  7. Novartis Contract Manufacturing Capacity Update July 2025: Large Molecule Drug Substance 7/28/2025

    Review biologics CDMO solutions and capacity offered by Novartis Contract Manufacturing. We discuss our capabilities in mammalian cell culture manufacturing and microbial fermentation.

  8. FUJIFILM Biotechnologies Capacity Update July 2025: Large Molecule Drug Substance 7/28/2025

    Review the strategic application of extensive expertise in microbial systems to meet the increasing demand for novel biologics. Cutting-edge capabilities ensure streamlined development and manufacturing processes.

  9. Cytovance Biologics Capacity Update July 2025: Large Molecule Drug Substance 7/28/2025

    Thomas Kohl, Director of Business Development, shares the company’s microbial and mammalian capabilities and their available capacity. Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients alike.

  10. Aragen Capacity Update July 2025: Large Molecule Drug Substance 7/28/2025

    Aragen’s newly built cutting-edge biologics manufacturing facility launches with GMP capabilities from 50L to 2000L—scaling to 5000L soon—with a DP filling line and ADC conjugation suite set to redefine bioproduction in India.